Lead
South African President Cyril Ramaphosa has hailed the rollout of lenacapavir, a twice-yearly injectable HIV prevention drug, as a "turning point" in the country's fight against the virus. The first doses are now being distributed across South Africa, which carries the highest burden of HIV globally, with over 8 million people living with the virus, according to Africa News.Speaking at the launch event at Lilian Ngoyi stadium in Secunda, Mpumalanga province, Ramaphosa said, "Now we have definitely moved away from denialism to treatment and now to elimination," as reported by Africa News. The rollout comes about a year and a half after US aid cuts affected some of South Africa's HIV programmes, the outlet noted.
Coverage comparison
Coverage of the rollout has been largely positive, focusing on the promise of a new prevention tool. Africa News emphasized the distribution details and the historical context of US aid cuts, while AllAfrica and RFI provided more detailed reporting on how the drug works, featuring expert commentary from infectious disease specialist Ndong Essomba Bitchoka, who oversees the HIV/AIDS and tuberculosis care unit at District Deido hospital in Douala, Cameroon.AllAfrica and RFI both highlighted questions of access and cost, noting that lenacapavir requires just two injections a year, reducing the need for daily pills. The drug works by preventing the assembly of the HIV virus's RNA molecules, which stops new HIV viruses from forming, according to the specialist.
Key Claims
- Lenacapavir is a new long-acting antiretroviral treatment for HIV prevention, requiring only two injections a year, as reported by multiple sources.
- South Africa has the world's largest HIV-positive population, with over 8 million people living with the virus, according to Africa News.
- The first batch of 37,920 doses is being distributed across 360 health facilities in six provinces with high HIV rates, per Africa News.
- The government has acquired 912,000 doses, sufficient for 456,000 people, funded by a $29 million Global Fund grant, according to Africa News.
- 40,000 doses have been made available in South Africa, with 1 million more to be supplied within 18 months, as reported by AllAfrica and RFI.
- Civil society organizations have called the rollout plan inadequate, asserting that at least 2 million doses are necessary to significantly affect new infection rates, according to Africa News.
Perspectives
Government and Public Health Officials view lenacapavir as a major advancement, with President Ramaphosa describing it as a turning point that moves the country from treatment toward elimination. The drug is expected to lower pill fatigue and missed doses, typical challenges for traditional oral prevention drugs.Medical Experts emphasize the drug's mechanism and its potential to maintain viral suppression over longer periods when combined with other medicines. However, they note that patients must first have their condition controlled with oral medication before switching to injections, as Ndong Essomba Bitchoka explained to RFI.
Civil Society Organizations express concern that the current supply is insufficient. They argue that at least 2 million doses are needed to significantly impact new infection rates, which currently range from 140,000 to 170,000 annually, according to Africa News.
International Observers highlight broader challenges, including cost and access. Lenacapavir is not yet available in many countries, such as Cameroon, and experts note that governments and financial partners often need to subsidize the treatment to make it accessible.